BIOMARIN PHARMACEUTICAL INC. — Lobbying Disclosure | Poliscope

BIOMARIN PHARMACEUTICAL INC.

View full entity profile (contributions, contracts, SEC) →

This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.

Lobbying Spend

$13.7M

Filings

147

Firms Hired

Active Period

2007–2026

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2026	$1,750,000	8	2
2025	$1,320,000	14	3
2024	$1,320,000	10	3
2023	$1,320,000	9	2
2022	$1,370,000	8	2
2021	$1,040,000	8	2
2020	$1,360,000	8	2
2019	$1,070,000	8	2
2018	$820,000	9	2
2017	$1,260,000	9	2
2016	$500,000	12	3
2015	$230,000	9	2
2014	$290,000	9	2
2013	$70,000	8	3
2012	—	4	1
2011	—	4	1
2010	—	4	1
2009	—	3	1
2007	—	3	1

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
BIOMARIN PHARMACEUTICAL INC.	$13,720,000	58
BGR GOVERNMENT AFFAIRS	—	16
CHAMBER HILL STRATEGIES	—	21
VENN STRATEGIES	—	20
LMH STRATEGIC SOLUTIONS	—	6
ENGEL & NOVITT, LLP	—	17
CONNECT 4 STRATEGIES, LLC	—	4
RUBICON ADVISORS, LLC	—	3
HOLLAND & KNIGHT LLP	—	2

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	117
SENATE	111
Health & Human Services, Dept of (HHS)	29
Food & Drug Administration (FDA)	21
Centers For Medicare and Medicaid Services (CMS)	14
Executive Office of the President (EOP)	5
Commerce, Dept of (DOC)	4
White House Office	4
Health Resources & Services Administration (HRSA)	3
Office of the Vice President of the United States	2
Government Accountability Office (GAO)	1
Homeland Security, Dept of (DHS)	1
U.S. Immigration & Customs Enforcement (ICE)	1

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Health Issues	Health Issues	117
Medicare/Medicaid	Medicare/Medicaid	70
Taxation/Internal Revenue Code	Taxation/Internal Revenue Code	63
Budget/Appropriations	Budget/Appropriations	17
Immigration	Immigration	16
Pharmacy	Pharmacy	12
Tariff (miscellaneous tariff bills)	Tariff (miscellaneous tariff bills)	9
Medical/Disease Research/Clinical Labs	Medical/Disease Research/Clinical Labs	5
Copyright/Patent/Trademark	Copyright/Patent/Trademark	2
Trade (domestic/foreign)	Trade (domestic/foreign)	2
Science/Technology	Science/Technology	1
Manufacturing	Manufacturing	1

Bills Explicitly Cited (25)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 10359119th Congress

Priority for Pediatric Cures Act

2026 · third_quarter · Firm: BIOMARIN PHARMACEUTICAL INC.

Open original LDA filing ↗

Cited source text and reported amounts

H.R.10359: PRIORITY FOR PEDIATRIC CURES ACT; PROVISIONS RELATED TO REMOVAL OF RARE PEDIATRIC PRIORITY REVIEW VOUCHERS SUNSET GENERAL DISCUSSIONS REGARDING CLINICAL TRIALS

Client expense: $200,000 · Firm income: —

Matched citations: H.R.10359

H.R. 10571119th Congress

Surge to Save Newborns Act

2026 · third_quarter · Firm: BIOMARIN PHARMACEUTICAL INC.

Open original LDA filing ↗

Cited source text and reported amounts

H.R.10571: SURGE TO SAVE NEWBORNS ACT; PROVISIONS RELATED TO NEWBORN SCREENING GENERAL DISCUSSIONS REGARDING ORPHAN DRUGS GENERAL DISCUSSIONS REGARDING GENETIC SCREENING AND TESTING

Client expense: $200,000 · Firm income: —

Matched citations: H.R.10571

H.R. 1414119th Congress

Cameron’s Law

2026 · third_quarter · Firm: BIOMARIN PHARMACEUTICAL INC.

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 1414: CAMERON'S LAW; ALL PROVISIONS

Client expense: $200,000 · Firm income: —

Matched citations: H.R. 1414

H.R. 1262119th Congress

Mikaela Naylon Give Kids a Chance Act

2025 · fourth_quarter · Firm: BIOMARIN PHARMACEUTICAL INC.

Open original LDA filing ↗

Cited source text and reported amounts

H.R.1262: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION S.932: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION GENERAL DISCUSSIONS REGARDING GENETIC SREENING AND NEWBORN SREENING GENERAL DISCUSSIONS REGARDING ORPHAN DRUGS GENERAL DISCUSSIONS RELATED TO MOST-FAVORED-NATION (MFN) DRUG PRICING GENERAL DISCUSSIONS RELATED TO THE PRIORITY REVIEW VOUCHER PROGRAM

Client expense: $390,000 · Firm income: —

Matched citations: H.R.1262

Show 21 more cited filings

H.R. 1509119th Congress

Accelerating Kids’ Access to Care Act of 2025

2025 · fourth_quarter · Firm: BIOMARIN PHARMACEUTICAL INC.

Open original LDA filing ↗

Cited source text and reported amounts

H.R.1509: ACCELERATING KIDS' ACCESS TO CARE ACT OF 2025; ALL PROVISIONS S.752: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS S.1637: MVP ACT; ALL PROVISIONS GENERAL DISCUSSIONS REGARDING MEDICAID DRUG REBATE PROGRAM GENERAL DISCUSSIONS REGARDING PRESCRIPTION DRUG REFERENCE PRICING

Client expense: $390,000 · Firm income: —

Matched citations: H.R.1509

H.R. 5371119th Congress

Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026

2025 · fourth_quarter · Firm: BIOMARIN PHARMACEUTICAL INC.

Open original LDA filing ↗

Cited source text and reported amounts

H.R.5371: CONTINUING APPROPRIATIONS, ARGICULTURE, LEGISLATIVE BRANCH, MILITARY CONSTRUCTION AND VETERANS AFFAIRS, AND EXTENSIONS ACT, 2026; PROVISIONS RELATED TO JOINT EXPLANTATORY STATEMENT, DIV. B

Client expense: $390,000 · Firm income: —

Matched citations: H.R.5371

S. 1637119th Congress

MVP Act

2025 · fourth_quarter · Firm: BIOMARIN PHARMACEUTICAL INC.

Open original LDA filing ↗

Cited source text and reported amounts

H.R.1509: ACCELERATING KIDS' ACCESS TO CARE ACT OF 2025; ALL PROVISIONS S.752: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS S.1637: MVP ACT; ALL PROVISIONS GENERAL DISCUSSIONS REGARDING MEDICAID DRUG REBATE PROGRAM GENERAL DISCUSSIONS REGARDING PRESCRIPTION DRUG REFERENCE PRICING

Client expense: $390,000 · Firm income: —

Matched citations: S.1637

S. 752119th Congress

Accelerating Kids’ Access to Care Act

2025 · fourth_quarter · Firm: BIOMARIN PHARMACEUTICAL INC.

Open original LDA filing ↗

Cited source text and reported amounts

H.R.1509: ACCELERATING KIDS' ACCESS TO CARE ACT OF 2025; ALL PROVISIONS S.752: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS S.1637: MVP ACT; ALL PROVISIONS GENERAL DISCUSSIONS REGARDING MEDICAID DRUG REBATE PROGRAM GENERAL DISCUSSIONS REGARDING PRESCRIPTION DRUG REFERENCE PRICING

Client expense: $390,000 · Firm income: —

Matched citations: S.752

S. 932119th Congress

Give Kids a Chance Act of 2025

2025 · fourth_quarter · Firm: BIOMARIN PHARMACEUTICAL INC.

Open original LDA filing ↗

Cited source text and reported amounts

H.R.1262: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION S.932: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION GENERAL DISCUSSIONS REGARDING GENETIC SREENING AND NEWBORN SREENING GENERAL DISCUSSIONS REGARDING ORPHAN DRUGS GENERAL DISCUSSIONS RELATED TO MOST-FAVORED-NATION (MFN) DRUG PRICING GENERAL DISCUSSIONS RELATED TO THE PRIORITY REVIEW VOUCHER PROGRAM

Client expense: $390,000 · Firm income: —

Matched citations: S.932

H.R. 1262119th Congress

Mikaela Naylon Give Kids a Chance Act

2025 · third_quarter · Firm: BIOMARIN PHARMACEUTICAL INC.

Open original LDA filing ↗

Cited source text and reported amounts

H.R.1262: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION S.932: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION GENERAL DISCUSSIONS REGARDING GENETIC SREENING AND NEWBORN SREENING GENERAL DISCUSSIONS REGARDING ORPHAN DRUGS GENERAL DISCUSSIONS RELATED TO MOST-FAVORED-NATION (MFN) DRUG PRICING GENERAL DISCUSSIONS RELATED TO THE PRIORITY REVIEW VOUCHER PROGRAM

Client expense: $270,000 · Firm income: —

Matched citations: H.R.1262

H.R. 1509119th Congress

Accelerating Kids’ Access to Care Act of 2025

2025 · third_quarter · Firm: BIOMARIN PHARMACEUTICAL INC.

Open original LDA filing ↗

Cited source text and reported amounts

H.R.1509: ACCELERATING KIDS' ACCESS TO CARE ACT OF 2025; ALL PROVISIONS S.752: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS S.1637: MVP ACT; ALL PROVISIONS GENERAL DISCUSSIONS REGARDING MEDICAID DRUG REBATE PROGRAM GENERAL DISCUSSIONS REGARDING FOREIGN DRUG REFERENCE PRICING

Client expense: $270,000 · Firm income: —

Matched citations: H.R.1509

S. 1637119th Congress

MVP Act

2025 · third_quarter · Firm: BIOMARIN PHARMACEUTICAL INC.

Open original LDA filing ↗

Cited source text and reported amounts

H.R.1509: ACCELERATING KIDS' ACCESS TO CARE ACT OF 2025; ALL PROVISIONS S.752: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS S.1637: MVP ACT; ALL PROVISIONS GENERAL DISCUSSIONS REGARDING MEDICAID DRUG REBATE PROGRAM GENERAL DISCUSSIONS REGARDING FOREIGN DRUG REFERENCE PRICING

Client expense: $270,000 · Firm income: —

Matched citations: S.1637

S. 752119th Congress

Accelerating Kids’ Access to Care Act

2025 · third_quarter · Firm: BIOMARIN PHARMACEUTICAL INC.

Open original LDA filing ↗

Cited source text and reported amounts

H.R.1509: ACCELERATING KIDS' ACCESS TO CARE ACT OF 2025; ALL PROVISIONS S.752: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS S.1637: MVP ACT; ALL PROVISIONS GENERAL DISCUSSIONS REGARDING MEDICAID DRUG REBATE PROGRAM GENERAL DISCUSSIONS REGARDING FOREIGN DRUG REFERENCE PRICING

Client expense: $270,000 · Firm income: —

Matched citations: S.752

S. 932119th Congress

Give Kids a Chance Act of 2025

2025 · third_quarter · Firm: BIOMARIN PHARMACEUTICAL INC.

Open original LDA filing ↗

Cited source text and reported amounts

H.R.1262: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION S.932: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION GENERAL DISCUSSIONS REGARDING GENETIC SREENING AND NEWBORN SREENING GENERAL DISCUSSIONS REGARDING ORPHAN DRUGS GENERAL DISCUSSIONS RELATED TO MOST-FAVORED-NATION (MFN) DRUG PRICING GENERAL DISCUSSIONS RELATED TO THE PRIORITY REVIEW VOUCHER PROGRAM

Client expense: $270,000 · Firm income: —

Matched citations: S.932

H.R. 1119th Congress

An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.

2025 · second_quarter · Firm: BIOMARIN PHARMACEUTICAL INC.

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 1: ONE BIG BEAUTIFUL BILL ACT; PROVISIONS RELATED TO TITLE VII, SUBTITLE B H.R. 946: ORPHAN Cures Act; ALL PROVISIONS H.R. 1509: ACCELERATING KIDS' ACCESS TO CARE ACT OF 2025; ALL PROVISIONS OF THE BILL S. 752: ACCELERATING KIDS' ACCESS TO CARE ACT OF 2025; ALL PROVISIONS OF THE BILL S. 1637: MEDICAID VBPS FOR PATIENTS (MVP) Act; ALL PROVISIONS S. 1862: ORPHAN Cures Act; ALL PROVISIONS GENERAL DISCUSSIONS REGARDING MEDICAID DRUG REBATE PROGRAM GENERAL DISCUSSIONS REGARDING FOREIGN DRUG REFERENCE PRICING

Client expense: $270,000 · Firm income: —

Matched citations: H.R. 1

H.R. 1262119th Congress

Mikaela Naylon Give Kids a Chance Act

2025 · second_quarter · Firm: BIOMARIN PHARMACEUTICAL INC.

Open original LDA filing ↗

Cited source text and reported amounts

HR 1262: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION S 932: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION GENERAL DISCUSSIONS REGARDING INFLATION REDUCTION ACT AND ORPHAN DRUGS GENERAL DISCUSSIONS REGARDING ORPHAN DRUG ACT GENERAL DISCUSSIONS REGARDING GENETIC SCREENING AND NEWBORN SCREENING

Client expense: $270,000 · Firm income: —

Matched citations: HR 1262

H.R. 1509119th Congress

Accelerating Kids’ Access to Care Act of 2025

2025 · second_quarter · Firm: BIOMARIN PHARMACEUTICAL INC.

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 1: ONE BIG BEAUTIFUL BILL ACT; PROVISIONS RELATED TO TITLE VII, SUBTITLE B H.R. 946: ORPHAN Cures Act; ALL PROVISIONS H.R. 1509: ACCELERATING KIDS' ACCESS TO CARE ACT OF 2025; ALL PROVISIONS OF THE BILL S. 752: ACCELERATING KIDS' ACCESS TO CARE ACT OF 2025; ALL PROVISIONS OF THE BILL S. 1637: MEDICAID VBPS FOR PATIENTS (MVP) Act; ALL PROVISIONS S. 1862: ORPHAN Cures Act; ALL PROVISIONS GENERAL DISCUSSIONS REGARDING MEDICAID DRUG REBATE PROGRAM GENERAL DISCUSSIONS REGARDING FOREIGN DRUG REFERENCE PRICING

Client expense: $270,000 · Firm income: —

Matched citations: H.R. 1509

H.R. 946119th Congress

ORPHAN Cures Act

2025 · second_quarter · Firm: BIOMARIN PHARMACEUTICAL INC.

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 1: ONE BIG BEAUTIFUL BILL ACT; PROVISIONS RELATED TO TITLE VII, SUBTITLE B H.R. 946: ORPHAN Cures Act; ALL PROVISIONS H.R. 1509: ACCELERATING KIDS' ACCESS TO CARE ACT OF 2025; ALL PROVISIONS OF THE BILL S. 752: ACCELERATING KIDS' ACCESS TO CARE ACT OF 2025; ALL PROVISIONS OF THE BILL S. 1637: MEDICAID VBPS FOR PATIENTS (MVP) Act; ALL PROVISIONS S. 1862: ORPHAN Cures Act; ALL PROVISIONS GENERAL DISCUSSIONS REGARDING MEDICAID DRUG REBATE PROGRAM GENERAL DISCUSSIONS REGARDING FOREIGN DRUG REFERENCE PRICING

Client expense: $270,000 · Firm income: —

Matched citations: H.R. 946

S. 1637119th Congress

MVP Act

2025 · second_quarter · Firm: BIOMARIN PHARMACEUTICAL INC.

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 1: ONE BIG BEAUTIFUL BILL ACT; PROVISIONS RELATED TO TITLE VII, SUBTITLE B H.R. 946: ORPHAN Cures Act; ALL PROVISIONS H.R. 1509: ACCELERATING KIDS' ACCESS TO CARE ACT OF 2025; ALL PROVISIONS OF THE BILL S. 752: ACCELERATING KIDS' ACCESS TO CARE ACT OF 2025; ALL PROVISIONS OF THE BILL S. 1637: MEDICAID VBPS FOR PATIENTS (MVP) Act; ALL PROVISIONS S. 1862: ORPHAN Cures Act; ALL PROVISIONS GENERAL DISCUSSIONS REGARDING MEDICAID DRUG REBATE PROGRAM GENERAL DISCUSSIONS REGARDING FOREIGN DRUG REFERENCE PRICING

Client expense: $270,000 · Firm income: —

Matched citations: S. 1637

S. 1862119th Congress

ORPHAN Cures Act

2025 · second_quarter · Firm: BIOMARIN PHARMACEUTICAL INC.

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 1: ONE BIG BEAUTIFUL BILL ACT; PROVISIONS RELATED TO TITLE VII, SUBTITLE B H.R. 946: ORPHAN Cures Act; ALL PROVISIONS H.R. 1509: ACCELERATING KIDS' ACCESS TO CARE ACT OF 2025; ALL PROVISIONS OF THE BILL S. 752: ACCELERATING KIDS' ACCESS TO CARE ACT OF 2025; ALL PROVISIONS OF THE BILL S. 1637: MEDICAID VBPS FOR PATIENTS (MVP) Act; ALL PROVISIONS S. 1862: ORPHAN Cures Act; ALL PROVISIONS GENERAL DISCUSSIONS REGARDING MEDICAID DRUG REBATE PROGRAM GENERAL DISCUSSIONS REGARDING FOREIGN DRUG REFERENCE PRICING

Client expense: $270,000 · Firm income: —

Matched citations: S. 1862

S. 752119th Congress

Accelerating Kids’ Access to Care Act

2025 · second_quarter · Firm: BIOMARIN PHARMACEUTICAL INC.

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 1: ONE BIG BEAUTIFUL BILL ACT; PROVISIONS RELATED TO TITLE VII, SUBTITLE B H.R. 946: ORPHAN Cures Act; ALL PROVISIONS H.R. 1509: ACCELERATING KIDS' ACCESS TO CARE ACT OF 2025; ALL PROVISIONS OF THE BILL S. 752: ACCELERATING KIDS' ACCESS TO CARE ACT OF 2025; ALL PROVISIONS OF THE BILL S. 1637: MEDICAID VBPS FOR PATIENTS (MVP) Act; ALL PROVISIONS S. 1862: ORPHAN Cures Act; ALL PROVISIONS GENERAL DISCUSSIONS REGARDING MEDICAID DRUG REBATE PROGRAM GENERAL DISCUSSIONS REGARDING FOREIGN DRUG REFERENCE PRICING

Client expense: $270,000 · Firm income: —

Matched citations: S. 752

S. 932119th Congress

Give Kids a Chance Act of 2025

2025 · second_quarter · Firm: BIOMARIN PHARMACEUTICAL INC.

Open original LDA filing ↗

Cited source text and reported amounts

HR 1262: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION S 932: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION GENERAL DISCUSSIONS REGARDING INFLATION REDUCTION ACT AND ORPHAN DRUGS GENERAL DISCUSSIONS REGARDING ORPHAN DRUG ACT GENERAL DISCUSSIONS REGARDING GENETIC SCREENING AND NEWBORN SCREENING

Client expense: $270,000 · Firm income: —

Matched citations: S 932

H.R. 1262119th Congress

Mikaela Naylon Give Kids a Chance Act

2025 · first_quarter · Firm: BIOMARIN PHARMACEUTICAL INC.

Open original LDA filing ↗

Cited source text and reported amounts

HR 1262: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION S 932: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION GENERAL DISCUSSIONS REGARDING ORPHAN DRUG ACT, HEALTH AND HUMAN SERVICES (HHS) RESTRUCTURING, MANUFACTURER-SPONSORED GENETIC SCREENING, PRIORITY REVIEW VOUCHER (PRV) EXTENSION, MEDICAID, NEWBORN SCREENING

Client expense: $390,000 · Firm income: —

Matched citations: HR 1262

H.R. 1509119th Congress

Accelerating Kids’ Access to Care Act of 2025

2025 · first_quarter · Firm: BIOMARIN PHARMACEUTICAL INC.

Open original LDA filing ↗

Cited source text and reported amounts

HR 1509: ACCELERATING KIDS' ACCESS TO CARE ACT OF 2025; ALL PROVISIONS OF THE BILL S 752: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING MEDICAID REFORM

Client expense: $390,000 · Firm income: —

Matched citations: HR 1509

S. 752119th Congress

Accelerating Kids’ Access to Care Act

2025 · first_quarter · Firm: BIOMARIN PHARMACEUTICAL INC.

Open original LDA filing ↗

Cited source text and reported amounts

HR 1509: ACCELERATING KIDS' ACCESS TO CARE ACT OF 2025; ALL PROVISIONS OF THE BILL S 752: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING MEDICAID REFORM

Client expense: $390,000 · Firm income: —

Matched citations: S 752

Source: Senate LDA